NCT05082025 2026-01-09
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
M.D. Anderson Cancer Center
Phase 2 Terminated
Clinical Trials
4 trialsNCT00006903 2019-03-20
Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer
GOG Foundation
Phase 2 Unknown
NCT00617188 2017-12-28
Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT00334295 2012-07-31
Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.
AstraZeneca
Phase 2 Completed